EUVIMEDUpptäck EUVIMED
Crossref

Diabetes vaccines: review of the clinical evidence

Johnny Ludvigsson

Clinical Investigation · 2011

DOI: 10.4155/cli.10.18 ↗

At a glance

Journal article in Clinical Investigation, 2011. Written by Johnny Ludvigsson. 97 references.

AbstractBibliografiska uppgifterCiteRelated studies

Abstract (original language)

As preservation of residual β-cell function is clinically important, such an effect constitutes clinical evidence. Traditional vaccination strengthening the immune reaction against an antigen/microbe may well be relevant for Type 1 diabetes (T1D) but progress takes time. Use of probiotics is another way of influencing the immune system at the border of ‘vaccination’. Methods of reducing a pathological-specific immune response, ‘inverse’ vaccination, are being developed. Use of insulin or its relatives (proinsulin and B-chain of insulin) is still experimental. Diapep277®, a heat shock protein, may modulate the immune system in a favorable way, and subcutaneous ‘vaccination’ with GAD-alum has shown encouraging results in T1D with recent onset. Perhaps autoantigens should be administered via DNA vaccines. It is possible that these will soon be part of clinical practice for the treatment of diabetes.

Cite

APA

Ludvigsson, J. (2011). Diabetes vaccines: review of the clinical evidence. Clinical Investigation. https://doi.org/10.4155/cli.10.18

Vancouver

Ludvigsson J. Diabetes vaccines: review of the clinical evidence. Clinical Investigation. 2011. doi:10.4155/cli.10.18

BibTeX
@article{Ludvigsson2011,
  author = {Ludvigsson, Johnny},
  title = {Diabetes vaccines: review of the clinical evidence},
  journal = {Clinical Investigation},
  year = {2011},
  doi = {10.4155/cli.10.18}
}
Start for free →